{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T23:55:57Z","timestamp":1793750157771,"version":"4.6.1"},"reference-count":41,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.clinthera.2016.01.018","type":"journal-article","created":{"date-parts":[[2016,3,3]],"date-time":"2016-03-03T01:39:42Z","timestamp":1456969182000},"page":"431-444","source":"Crossref","is-referenced-by-count":103,"title":["Ceftazidime-Avibactam: A Novel Cephalosporin\/\u03b2-Lactamase Inhibitor Combination for the Treatment of Resistant Gram-negative Organisms"],"prefix":"10.1016","volume":"38","author":[{"given":"Roopali","family":"Sharma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae Eun","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley","family":"Moy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2016.01.018_bib1","unstructured":"Centers for Disease Control and Prevention (CDC). Antibiotic resistance treats in the United States, 2013. http:\/\/www.cdc.gov\/drugresistance\/threat-report-2013\/pdf\/ar-threats-2013-508.pdf. Accessed September 6, 2015."},{"key":"10.1016\/j.clinthera.2016.01.018_bib2","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/cc8892","article-title":"Bench-to-bedside review: the role of beta-lactamases in antibiotic-resistant Gram-negative infections","volume":"14","author":"Bush","year":"2010","journal-title":"Crit Care"},{"key":"10.1016\/j.clinthera.2016.01.018_bib3","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1128\/AAC.01009-09","article-title":"Updated functional classification of \u03b2-lactamases","volume":"54","author":"Bush","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2016.01.018_bib4","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1128\/CMR.18.4.657-686.2005","article-title":"Extended-spectrum \u03b2-lactamases: a clinical update","volume":"18","author":"Paterson","year":"2005","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.clinthera.2016.01.018_bib5","year":"2007"},{"key":"10.1016\/j.clinthera.2016.01.018_bib6","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.mib.2010.09.006","article-title":"Alarming beta-lactamase-mediated resistance in multi-drug-resistant Enterobacteriaceae","volume":"13","author":"Bush","year":"2010","journal-title":"Curr Opin Microbiol"},{"key":"10.1016\/j.clinthera.2016.01.018_bib7","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2165\/11533040-000000000-00000","article-title":"Infections with extended-spectrum beta-lactamase-producing Enterobacteriaceae: changing epidemiology and drug treatment choices","volume":"70","author":"Pitout","year":"2010","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2016.01.018_bib8","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.tim.2006.07.008","article-title":"The beta-lactamase threat in Enterobacteriaceae, Pseudomonas and Acinetobacter","volume":"14","author":"Livermore","year":"2006","journal-title":"Trends Microbiol"},{"key":"10.1016\/j.clinthera.2016.01.018_bib9","unstructured":"Center for Drug Evaluation and Research, US Food and Drug Administration. Avycaz (ceftazidime\u2013avibactam) FDA summary review. http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/Anti-InfectiveDrugsAdvisoryCommittee\/UCM425458.pdf. Accessed October 5, 2015."},{"key":"10.1016\/j.clinthera.2016.01.018_bib10","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1128\/AAC.00641-09","article-title":"In vitro activity of NXL104 in combination with beta-lactams against Klebsiella pneumoniae isolates producing KPC carbapenemases","volume":"53","author":"Endimiani","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2016.01.018_bib11","series-title":"Avycaz\u00ae (ceftazidime\/avibactam) [package insert] Cincinnati","year":"2015"},{"key":"10.1016\/j.clinthera.2016.01.018_bib12","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2147\/CE.S40698","article-title":"Ceftazidime-avibactam: an evidence-based review of its pharmacology and potential use in the treatment of Gram-negative bacterial infections","volume":"9","author":"Lagac\u00e9-Wiens","year":"2014","journal-title":"Core Evid"},{"key":"10.1016\/j.clinthera.2016.01.018_bib13","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/phar.1622","article-title":"The \u03b2-lactams strike back: ceftazidime-avibactam","volume":"35","author":"Zasowski","year":"2015","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.clinthera.2016.01.018_bib14","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/nrmicro3088","article-title":"How to get (a)round: mechanisms controlling growth and division of coccoid bacteria","volume":"11","author":"Pinho","year":"2013","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.clinthera.2016.01.018_bib15","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1574-6976.2008.00105.x","article-title":"The penicillin-binding proteins: structure and role in peptidoglycan biosynthesis","volume":"32","author":"Sauvage","year":"2008","journal-title":"FEMS Microbiol Rev"},{"key":"10.1016\/j.clinthera.2016.01.018_bib16","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/j.1574-6976.2006.00024.x","article-title":"Penicillin binding proteins: key players in bacterial cell cycle and drug resistance processes","volume":"30","author":"Macheboeuf","year":"2006","journal-title":"FEMS Microbiol Rev"},{"key":"10.1016\/j.clinthera.2016.01.018_bib17","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1128\/CMR.00037-09","article-title":"Three decades of beta-lactamase inhibitors","volume":"23","author":"Drawz","year":"2010","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.clinthera.2016.01.018_bib18","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1128\/AAC.02247-12","article-title":"Structural insight into portent broad-spectrum inhibition with reversible recyclization mechanism: avibactam in complex with CTX-M-15 and Pseudomonas aeruginosa AmpC beta-lactamases","volume":"57","author":"Lahiri","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2016.01.018_bib19","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.1128\/AAC.00163-15","article-title":"Ceftazidime-avibactam activity tested against Enterobacteriaceae isolates from U.S. hospitals (2011 to 2013) and characterization of \u03b2-lactamase-producing strains","volume":"59","author":"Castanheira","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2016.01.018_bib20","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.diagmicrobio.2014.07.005","article-title":"Ceftazidime-avibactam and comparator agents tested against urinary tract isolates from a global surveillance program (2011)","volume":"80","author":"Flamm","year":"2014","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.clinthera.2016.01.018_bib21","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1128\/AAC.06064-11","article-title":"In vitro antibacterial activity of the ceftazidime-avibactam (NXL104) combination against Pseudomonas aeruginosa clinical isolates","volume":"56","author":"Levasseur","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2016.01.018_bib22","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1128\/AAC.05136-14","article-title":"Activity of ceftazidime-avibactam against fluoroquinolone-resistant Enterobacteriaceae and Pseudomonas aeruginosa","volume":"59","author":"Pitart","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2016.01.018_bib23","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ijantimicag.2015.02.022","article-title":"Ceftazidime\/avibactam tested against gram-negative bacteria from intensive care unit (ICU) and non-ICU patients, including those with ventilator-associated pneumonia","volume":"46","author":"Sader","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.clinthera.2016.01.018_bib24","doi-asserted-by":"crossref","first-page":"3656","DOI":"10.1128\/AAC.05024-14","article-title":"Ceftazidime-avibactam activity against multidrug-resistant Pseudomonas aeruginosa isolated in U.S. medical centers in 2012 and 2013","volume":"59","author":"Sader","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2016.01.018_bib25","doi-asserted-by":"crossref","first-page":"5793","DOI":"10.1128\/AAC.00548-15","article-title":"Effects of Klebsiella pneumoniae carbapenemase subtypes, extended-spectrum \u03b2-lactamases, and porin mutations on the in vitro activity of ceftazidime-avibactam against carbapenem-resistant K. pneumoniae","volume":"59","author":"Shields","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2016.01.018_bib26","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.ijantimicag.2014.12.033","article-title":"In vitro activity of ceftazidime, ceftaroline and aztreonam alone and in combination with avibactam against European gram-negative and gram-positive clinical isolates","volume":"45","author":"Testa","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.clinthera.2016.01.018_bib27","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1128\/AAC.01682-10","article-title":"In vitro activity of ceftazidime-NXL104 against 396 strains of beta-lactamase-producing anaerobes","volume":"55","author":"Citron","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2016.01.018_bib28","doi-asserted-by":"crossref","unstructured":"Sader HS, Castanheira M, Flamm RK, et al. Ceftazidime-avibactam activity tested against aerobic gram-negative organisms isolated from intraabdominal infections in United States hospitals (2012\u20132014). Abstract presented at: Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC); September 17\u201321, 2015; San Diego, CA. Abstract C-140.","DOI":"10.1089\/sur.2016.036"},{"key":"10.1016\/j.clinthera.2016.01.018_bib29","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s40261-015-0283-9","article-title":"Safety and pharmacokinetics of single and multiple ascending doses of avibactam alone and in combination with ceftazidime in healthy male volunteers: results of two randomized, placebo-controlled studies","volume":"35","author":"Merdjan","year":"2015","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.clinthera.2016.01.018_bib30","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.jiac.2015.04.006","article-title":"Phase I study assessing the safety, tolerability, and pharmacokinetics of avibactam and ceftazidime-avibactam in healthy Japanese volunteers","volume":"21","author":"Tominaga","year":"2015","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.clinthera.2016.01.018_bib31","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1124\/dmd.113.055335","article-title":"Assessment of the mass balance recovery and metabolite profile of avibactam in humans and in vitro drug-drug interaction potential","volume":"42","author":"Vishwanathan","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.clinthera.2016.01.018_bib32","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.ijantimicag.2014.07.023","article-title":"Microbiological interaction studies between ceftazidime-avibactam and pulmonary surfactant and between ceftazidime-avibactam and antibacterial agents of other classes","volume":"44","author":"Dallow","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.clinthera.2016.01.018_bib33","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1093\/jac\/dks523","article-title":"Comparative study of the efficacy and safety of ceftazidime\/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trial","volume":"68","author":"Lucasti","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2016.01.018_bib34","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1185\/03007995.2012.748653","article-title":"Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study","volume":"28","author":"Vazquez","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2016.01.018_bib35","unstructured":"Mazuski JE, Gasnik L, Armstrong J, et al. Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection\u2014results from a Phase III program. Abstract presented at: 25th European Congress of Clinical Microbiology and Infectious Diseases; April 25-28, 2015; Copenhagen, Denmark. Abstract O191."},{"key":"10.1016\/j.clinthera.2016.01.018_bib36","unstructured":"Carmeli Y, Armstrong J, Laud PJ, et al. Efficacy and safety of ceftazidime-avibactam and best available therapy in the treatment of ceftazidime-resistant infections\u2014results from a Phase III study. Abstract presented at: 25th European Congress of Clinical Microbiology and Infectious Diseases; April 25\u201328, 2015; Copenhagen, Denmark. Abstract LBEV0061b."},{"key":"10.1016\/j.clinthera.2016.01.018_bib37","unstructured":"ClinicalTrials.gov. Ceftazidime-avibactam compared with doripenem followed by oral therapy for hospitalized adults with complicated UTIs. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01599806. Accessed August 26, 2015."},{"key":"10.1016\/j.clinthera.2016.01.018_bib38","unstructured":"ClinicalTrials.gov. Ceftazidime-avibactam compared with doripenem followed by oral therapy for hospitalized adults with complicated UTIs. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01595438. Accessed August 26, 2015."},{"key":"10.1016\/j.clinthera.2016.01.018_bib39","unstructured":"ClinicalTrials.gov. A study comparing ceftazidime\u2013avibactam versus meropenem in hospitalized adults with nosocomial pneumonia. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01808092. Accessed August 26, 2015."},{"key":"10.1016\/j.clinthera.2016.01.018_bib40","unstructured":"Gallagher JC., Cprek J, Famon E, et al. Compassionate use ceftazidime\/avibactam (CAZ-AVI) for carbapenem-resistant Klebsiella pneumoniae (CRKP) infections. Abstract presented at: 18th Making a Difference in Infectious Diseases (MAD-ID) Meeting; May 7\u20139, 2015; Orlando, FL."},{"key":"10.1016\/j.clinthera.2016.01.018_bib41","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/jcph.199","article-title":"Randomized, placebo-controlled study to assess the impact on QT\/QTc interval of supratherapeutic doses of ceftazidime-avibactam or ceftaroline fosamil-avibactam","volume":"54","author":"Das","year":"2014","journal-title":"J Clin Pharmacol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291816300418?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291816300418?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,5]],"date-time":"2019-09-05T01:56:58Z","timestamp":1567648618000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291816300418"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["S0149291816300418"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2016.01.018","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]}}}